Exelixis
EXEL
#2109
Rank
C$10.22 B
Marketcap
$35.84
Share price
-1.53%
Change (1 day)
23.67%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total liabilities

Total liabilities on the balance sheet as of June 2024 : C$0.88 B

According to Exelixis's latest financial reports the company's total liabilities are C$0.88 B. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Exelixis - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31C$0.89 B13.74%
2022-12-31C$0.79 B54.12%
2021-12-31C$0.51 B55.9%
2020-12-31C$0.32 B27.2%
2019-12-31C$0.25 B40.75%
2018-12-31C$0.18 B-60.5%
2017-12-31C$0.46 B-31.58%
2016-12-31C$0.68 B3.58%
2015-12-31C$0.65 B29.31%
2014-12-31C$0.50 B9.28%
2013-12-31C$0.46 B9.86%
2012-12-31C$0.42 B37.49%
2011-12-31C$0.30 B-47.8%
2010-12-31C$0.58 B10.37%
2009-12-31C$0.53 B-4.51%
2008-12-31C$0.55 B74.72%
2007-12-31C$0.32 B-9.77%
2006-12-31C$0.35 B10.68%
2005-12-31C$0.32 B22.1%
2004-12-31C$0.26 B2.05%
2003-12-31C$0.25 B-0.16%
2002-12-31C$0.25 B47.9%
2001-12-31C$0.17 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
C$76.01 B 8,477.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
C$82.52 B 9,212.05%๐Ÿ‡ซ๐Ÿ‡ท France
C$93.56 B 10,457.60%๐Ÿ‡บ๐Ÿ‡ธ USA
C$105.22 B 11,773.06%๐Ÿ‡บ๐Ÿ‡ธ USA
C$115.26 B 12,906.38%๐Ÿ‡บ๐Ÿ‡ธ USA
C$148.59 B 16,666.48%๐Ÿ‡บ๐Ÿ‡ธ USA
C$173.91 B 19,523.59%๐Ÿ‡บ๐Ÿ‡ธ USA
C$69.32 M-92.18%๐Ÿ‡บ๐Ÿ‡ธ USA
C$98.18 M-88.92%๐Ÿ‡บ๐Ÿ‡ธ USA